MHRA Appoints First Chief Medical and Scientific Officer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today welcomed Professor Jacob George as its inaugural Chief Medical and Scientific Officer (CMSO), effective from 5 January 2026. His appointment underscores the agency’s commitment to enhancing scientific excellence and innovation in the UK’s life sciences sector, while ensuring patient safety remains a priority.
Role and Responsibilities
As the CMSO, Professor George will spearhead the MHRA’s science strategy, guiding its scientific research and innovation initiatives. This new position is pivotal in aligning the agency with the UK’s broader ambitions for advancement in life sciences.
About Professor Jacob George
Professor George brings a wealth of experience to the role, serving as a Professor of Cardiovascular Medicine and Therapeutics at the University of Dundee, in addition to his position as a consultant physician for NHS Tayside. His extensive background includes being a member of the Delivery Group for the Innovative Licensing and Access Pathway (ILAP) and co-chairing the National Institute for Health Research (NIHR) Capital Investment Funding Committee. He has also advised on health technology matters for the National Institute for Health and Care Excellence (NICE).
Notably, in 2017, he was appointed by Malaysia’s Minister of Health as an International Expert Advisory Member for the Malaysian Scientific Review Panel on Phase I Clinical Trials, reflecting his international profile in medical research.
Support from Officials
Health Innovation Minister Dr Zubir Ahmed
Dr Zubir Ahmed, the Health Innovation Minister, expressed his enthusiasm regarding Professor George’s appointment. He emphasised the critical role of the MHRA in facilitating swift and safe access to new treatments, highlighting Professor George’s expertise as instrumental in advancing this objective. Dr Ahmed spoke of the UK’s aspirations to lead in life sciences and the necessity for rigorous scientific standards in regulating medical products.
Lawrence Tallon, Chief Executive of the MHRA
Lawrence Tallon, the Chief Executive of the MHRA, also welcomed Professor George, noting that his leadership will help set new benchmarks for the agency’s regulatory practices. Tallon pointed out the agency’s intent to safeguard public health and enhance access to medical therapies throughout the UK.
Statements from Professor Jacob George
Upon his appointment, Professor George expressed his excitement for joining the agency at a significant juncture for both science and regulatory practices. He reiterated the agency’s essential functions in protecting patient safety and fostering innovation, and he looks forward to collaborating with colleagues across the UK to bolster trust in scientific regulatory processes.
Background
The establishment of the CMSO role at the MHRA signals a strategic move to strengthen the agency’s scientific capabilities amid evolving challenges in the life sciences sector. The UK government aims to fortify the nation’s position as a leader in health innovation, particularly following the recent global health crises that have emphasized the importance of effective regulatory frameworks.
Source: official statements, news agencies, and public reports.
https://www.gov.uk/government/news/mhra-welcomes-professor-jacob-george-as-he-starts-chief-medical-and-scientific-officer-role
